Abstract This review article summarizes historical development of stem cell research, presents current knowledge on the plasticity potential of both embryonic and adult stem cells and discusses on the future of stem cell based therapies.
Introduction
Stem cells (SC) are distinguished by their potential for selfrenewal and multi-lineage differentiation. Concerning their state of development it is possible to distinguish embryonic stem (ES) cells from adult stem (AS) cells. While AS cells are responsible for maintenance and repair of most adult tissues. ES cells normally exist only in preimplantation embryos (4-8 cell stage to blastocyst) and have the ability to form all the cells of the body. ES cells could be used to set up cell lines in-vitro, to explore, for example, the function of genes. Biomedical research on SC is at an early stage, but is advancing rapidly. This promising area of science is very attractive for the investigation of the possibility of cell-based therapies. However, we are at the very beginning of understanding how SC influence the organism to keep its balance.
There are many regulation systems involved, which dictate the replacement of damaged, aged or diseased tissues with new cells.
It could be shown that there are factors secreted by SC, which act from the distance [1] and it was postulated that trophic factors play a role in tissue regeneration [2] . As it could be shown recently [3] , systemic factors in an organism also play a crucial role in modulating signalling pathways critical to the activation of tissue-specific SC. It seems that SC retain much of their intrinsic proliferative potential even when old, but that age-related changes in the systemic environment and niche in which SC reside preclude full activation of these cells for productive tissue regeneration. Besides the environment with its systemic factors, it is clear that there are certain genes controlling the action of SC and their aging [4] .
History of stem cell research
The history concerning SC research did not follow a straight path. A lot of other scientific disciplines in biomedicine exerted and still exert great influence on this special topic. The history of ES cells is tightly connected with outcomes and methods of studies on early embryonic development of different organism and in-vitro fertilization strategies. In contrast, works on AS cells are in close context of aging, cell repair strategies and haematopoiesis.
The beginning of SC research can be dated back to Ernst Neumann, who was appointed professor of pathology at Königsberg in 1866 and described in a preliminary communication [5] , the presence of nucleated red blood cells in bone marrow (BM) saps. He concluded in his subsequent papers, that during postembryonic life, erythropoiesis and leukopoiesis are taking place in the BM. On the basis of his observation, Ernst Neumann was the first to postulate the BM as blood forming organ with a common SC for all hematopoietic cells. Walter Heap succeeded for the first time in 1890 in generating live born rabbits by culturing embryos to the blastocysts stage and transferring them back into the uterus [6] . Further studies followed to increase the understanding of mammalian early development and the capacity of isolated blastomeres to develop into viable embryos [7] [8] [9] [10] [11] [12] , which also included observations on scarce human embryos [13] . In 1957, the era of Robert G. Edwards begun. In that year he started his scientific career as a PhD student in Alan Beatty's laboratory (Institute of Animal Genetics, Edinburgh), who worked on producing haploid, triploid and tetraploid embryos by warming fertilized mouse oocytes [14] . His first work, producing androgenetic and gynogenetic haploid embryos, triploids, tetraploids and various heteroploids [15] , was influenced by the work of Alexander A. Maximow, who was manipulating mammalian embryos in vitro [16] . Krzysztof Tarkowski from Warsaw published a study on regulation in the development of isolated blastomeres of the mouse in 1959 [17] and aggregated mechanically denuded mouse morulae in pairs to obtain giant blastocysts, some of which developed normally to term following transfer to uterine foster-mothers [18] . Subsequently, Beatrice Mintz introduced various technical improvements that enabled chimaeric mice to be produced routinely [19] . These studies and findings of others were among the first hints on the large potency of mammalian blastomeres and led R. G. Edwards to begin work on individual blastomeres in the rabbit model to search for new approaches to establish SC lines. His initial studies were undertaken in collaboration with Robin Cole, who was one of the first to perform studies on the outgrowths from rabbit blastocysts and inner cell mass (ICM) [20] and John Paul, who provided the facility to culture his cells [21] . One of his students, Richard Gardner, could refine the work of K. Tarkowski and B. Mintz by obtaining chimaeras after injecting embryonic cells into blastocysts (injection chimaeras) [22] instead of fusing blastomeres or morulae (fusion chimaeras) to produce chimaeras. With this, the value of chimaeras for studying development was enhanced and resulted in being the standard way for obtaining germline transmission of genetically modified ES cells [23] . Chimaeras helped in clarifying cell allocations to various tissues [24] [25] [26] [27] and widened the scope of analyses on clonal differentiation of tissues [28] [29] [30] . The next milestone influencing SC research was the birth of the first baby after in-vitro fertilisation (IVF) in 1978 [31] . In 1984, the first human ES cells were reported to be derived from ICM cells of day 5 blastocysts [32] and were "among the primary intentions of introducing human IVF" [33] . Thomson's group who published the culture of human ES cells in 1998 [34] used methods virtually identical to the rabbit models used by Cole RJ et al. in Glasgow, Scotland, 30 years earlier [20] , methods, which were also of utmost importance to establish the first SC lines from mouse embryos in 1981 [35] .
A few years later AS cells attracted more and more the intention of scientists. Studies on the grafting potentials of the earliest stages of haematopoietic stem cells (HSC) were carried out by a PhD student of Edwards, Peter Hollands, who could follow the migratory path of such cells from the yolk sac and injected into the tail vein of the mouse to the liver, spleen and BM [36, 37] . He then already postulated that such cells could also migrate to other sites of the embryo [33] . The circle, starting in the adult setting with the proposal of a common SC in the blood by Ernst Neumann, followed by such studies as listed above, first in animal models and later in the human using embryos to study the fate of embryonic cells now closes with the idea, that the 4-cell stage embryo might already harbor one blastomere from where SC origin and distribute to numerous tissues including gonads [38, 39] .
Plasticity of stem cells
Injection of ES cells into blastocysts is commonly used to generate chimaeras thus providing the most convincing evidence for stem cell plasticity [22] . Since the publica- [42] and Harder et al. [43, 44] further substantiate such findings. Both groups focused on HSC injected into blastocyst and their contribution to haematopoiesis. More recently, Durr et al. [45] were able to demonstrate erythroid marker expression after injecting acute myeloid leukaemia cells into murine blastocysts. The differentiation potential of microinjected cardiac SC into murine blastocysts was investigated by Oh et al. [46] . However, all these studies, demonstrating the ability of AS cells microinjected into blastocysts to contribute to further development did not include the characterization of such cells from the very beginning, when donor cells start attaching to the ICM and then further follow and characterize their invasion path. In a study intended to establish a system that helps in identifying and further characterizing AS cells in the earliest stages of interaction and integration into a conductive environment, such as a murine blastocyst we could show that after injection of CD34 positive human HSC into mouse blastocysts some of these cells attach to the ICM [47, 48] (Fig. 1) .
Taken all those findings on AS cells so far together, the contribution of AS cells to organs/tissues from all these Several more recent reports have also challenged the general concept that AS cells are plastic and trans-differentiate into other tissues [49] [50] [51] [52] . Studies by Clarke et al. [53] and Galli et al. [52] have shown that myoblast cells or embryoid bodies co-cultured with neuronal SC labelled with β-galactosidase produced β-galactosidase labelled muscle cells. This was interpreted as evidence that SC received signals that caused them to trans-differentiate into muscle cells. The paper by Ying et al. [53] as well as other papers [54, 55] alerted investigators to the possibility that perhaps all instances of trans-differentiation were the result of fusion. In Ying's experiments, a low frequency of fusion was observed when mouse central nerve SC were mixed with ES cells. They could show that the interpretations by Clarke and Galli were wrong, and that there were no signals, but that a fusion had occurred. Another explanation of SC plasticity is based on a possibility of the appearance of epigenetic changes in cells exposed to external stimuli (e.g., organ damage, unphysiological culture conditions or stress) [56] . Both cell fusion and epigenetic changes, however, are extremely rare and randomly occurring events that may not fully account for the previously published positive transdifferentiation data. Furthermore, fusion as a major contributor to the observed donor-derived chimerism was excluded in several recently published studies [59] [60] [61] [62] [63] [64] [65] . Besides, ES cells could reside in adult organs/tissues as was already postulated almost 150 years ago by Rudolf Virchow and Julius Connheim. They hypothesized that adult tissues may contain embryonic remnants that were 'lost' during developmental organogenesis and lie dormant. They also postulated that this population of dormant embryonic cells may give rise to some malignancies [66] . This concept was recently presented by some other investigators [52, 67] . ES cells could in fact reside as a rare and dormant cell population in adult tissues [68, 69] . In support of this, it was demonstrated that adult tissues contain embryonic-like SC [70] [71] [72] [73] [74] [75] with the expression of Oct-4 protein -which is a marker of pluripotent ES cells -at least in adult human hair follicles [71] lung epithelium [72] , heart tissue and adult testes [73] . However, they were never isolated and characterized at the single-cell level. Furthermore, Kucia et al. [70] provided direct evidence that a homogenous rare population of cells in murine BM, termed very small embryonic-like (VSEL) SC, have the morphology and express several markers of undifferentiated embryoniclike SC such as the transcription factor Oct-4. Cells with a very similar morphology and markers to murine BM-derived VSELs were also recently described by the same group in human umbilical cord blood (UCB) [76] .
The future in SC based therapies
There are now more than 1,000 SC based therapies in early human trials around the world. Until now, the vast majority of therapies are conducted with SC from patients' own BM or coming from cord blood banks. There are also intentions of some companies to begin first human trials soon using ES cells. After years of being thought of as science fiction -the domain of animal labs and the distant future-embryonic as well as adult SC-based therapies are increasingly becoming a scientific fact.
Therapies utilizing ES cells
ES cell lines are the in-vitro manifestation of cells of the ICM derived from blastocysts. Apart from ethical and moral concerns, ES cells can be expanded and then differentiated into most cell lineages of a living organism -making them a virtually unlimited source for cell replacement therapy. In practice, however, it remains almost an art to coax ES cells into generating specific cell types. It has been suggested that ES cells are likely to be distinct from ICM cells and may be more closely related to epiblast cells or embryonic germ cells (which are the in-vitro manifestation of primordial germ cells) [77] . Until now, the tumour-forming potential of ES cells has proved a significant problem for realising therapeutic applications. Numerous papers over the last few years have shown tumour formation in animals treated with differentiated ES cells derivatives [35, [78] [79] [80] [81] [82] . However, there are also more and more publications on strategies to purify differentiating and differentiated derivatives of ES cells with the intention to get rid of those cells, which still harbour the risk of tumour formation [83] [84] [85] [86] [87] [88] [89] . Also the site of transplantation [90] [91] [92] and the number of transplanted cells [83, 92, 93] have to be taken into consideration. For instance, Koch et al. [83] reported that for observing tumour formation administration of at least ×10 5 cells was required. They postulated that a larger number of cells establish a microenvironment, perhaps an aggregate of cells, into which complement penetrates poorly, conducive to the survival of "protected" cells. in-vitro cultivation itself, animal additives in the media and feeder cells also pose risks for the transplantation setting. All these factors bear the risk of being mutagenic and that cells loose their immunologic acceptance, thus becoming useless for clinical application. These methodical problems are all under investigation and will hopefully be solved some time soon. Even if all mentioned problem were solved there is still the fact, that ES cells are not autologous except ES cell lines set up by "therapeutically cloning" -and for that reason they could cause an immunologic reaction.
Therapies utilising AS cells AS cells, especially HSC were routinely used for transplantation. In 1957, the first BM transplantation with intravenous infusion of HSC was reported [94] . Most of the reports concerning AS cells plasticity were undertaken with HSC. These cells are relatively easily accessible in large amounts from BM or UCB without harming the patient, and are well characterized by several specific surface markers. It had been postulated that some of the AS cells found in the hematopoietic system possess germ-layer unrestricted plasticity and may trans-differentiate into SC from all non-hematopoietic lineages. Nowadays it is well established that UCB-derived cells contribute to multiple tissue-regenerations and recently, multiorgan engraftment [95] [96] [97] [98] [99] . Besides HSCs there also exists the ability to isolate mesenchymal stem cells (MSC) [100] [101] [102] and monocyte-derived SC [103] . It was also recently possible to generate AS cells expressing ES cell lineage markers after in-vitro culture of UCB-derived cells [104] or amniotic fluid cells [105, 106] and sharing properties with human ES cells including differentiation capabilities [107] . One of the biggest advantages to use AS cells is that an autologous transplantation is possible. Donor and recipient could be one person. If the high development potential of AS cells is caused by trans-differentiation or cell fusion is unclear yet, but both events seem to be important for regenerating damaged organs.
Conclusion
Still, much has to be learned on similarities or differences by directly comparing gene expression profiles of differentiated ES cells to isolate AS cells. It is important to know which stages of development of differentiating ES cells correspond to the various differentiation stages of AS cells. This knowledge is crucial for developing optimised culture conditions to generate differentiated or trans-differentiated AS cells as well as ES cells. These studies have to be carried out with cells cultured under GMP-compatible conditions to define comparability, which, until now, does not exist worldwide.
